This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
BackgroundInfective endocarditis (IE) is still a fatal disease, and given its rarity, ongoing updates to patient characteristics and outcomes of IE are essential for providing precision diagnoses and effective treatments. per 100 000 population in 2021. A total of 17 407 patients with IE (37.8% The incidence of IE increased from 2.02
Despite proven benefits in reducing morbidity and mortality, many heartfailure (HF) patients do not receive optimal guideline-directed medical therapy (GDMT). The 2021 European Society of Cardiology guidelines recommend guideline-directed medical therapy (GDMT) for patients with HF with reduced ejection fraction (HFrEF).
Heartfailure (HF) is a highly prevalent long-term condition, with variation in services and resources across the UK. This report provides findings from a cross-sectional survey of community HF services in the UK between September 2021 and February 2022. Eighty-five responses describing community HF services were received.
Discontinuation and reinitiation of mineralocorticoid receptor antagonists (MRA) in patients with heartfailure and reduced ejection fraction (HFrEF). BMI, body mass index; eGFR, estimated glomerular filtration rate; NYHA, New York Heart Association.
By 2021 almost half of patients younger than 60 years were receiving TAVR rather than SAVR. years after SAVR to assess their outcomes. Secondary outcomes included rates of reoperation, infective endocarditis, stroke, and hospital admissions for heartfailure. years after TAVR and 4.9
For this new study, published in JAMA Cardiology , investigators applied AI to identify tricuspid regurgitation, a condition in which the hearts tricuspid valve doesnt close fully when the heart contracts, causing blood to flow backward, which can result in heartfailure.
Research design and methods All patients with diabetes and CAD undergoing a coronary angiography between 2010 and 2021 according to the Swedish Angiography and Angioplasty Registry were included. Information on GLD (dispended 6 months before or after coronary angiography) was collected from the Swedish Prescribed Drug Registry.
Current Role of Digoxin in HeartFailure as Per Guidelines and DIGIT-HF trial of Digitoxin Use of digoxin in heartfailure has come down markedly over the past decades due to concerns of toxicity and availability of more effective medications. Eur Heart J. 2021 Sep 21;42(36):3599-3726. Eur J Heart Fail.
Circulation: Cardiovascular Quality and Outcomes, Ahead of Print. BACKGROUND:The absence of practice standards in vasoactive agent usage for acute decompensated heartfailure has resulted in significant treatment variability across hospitals, potentially affecting patient outcomes. in 2021 (Ptrend<0.001).
Cardiac amyloidosis is a heterogeneous disease that results from the accumulation of abnormal proteins within the heart, impairing its ability to pump blood. Over time, the build-up of these proteins causes the heart muscle to stiffen, eventually leading to heartfailure, which can have dire outcomes if not found early.
Knowledge and application of European Society of Cardiology/HeartFailure Association (ESC/HFA) guidelines in the management of advanced heartfailure (HF). Respondents were categorized into heartfailure cardiologists (HFCs), general cardiologists (GCs), and other participants (OPs).
Aims Heartfailure (HF) is associated with comorbidities which independently influence treatment response and outcomes. Methods Patients acted as their own controls, with outcomes compared for equal periods (for each patient) pre (HF MDT) versus post-MDT (multispecialty) meeting. Results 334 patients (mean age 72.5±11
There are conflicting sources regarding the relationship between hyperglycemia and outcomes in STEMI patients. We aimed to compile evidence to assess the association between hyperglycemia and adverse outcomes. Mortality was the most often outcome reported related to hyperglycemia. 2.17), heartfailure (pooled RR 1.56, 95% CI: 1.37–1.77),
Abstract Aims The COVID-19 pandemic disrupted healthcare systems and possibly impacted the management of heartfailure (HF). This study examined the impact of the pandemic on HF hospitalization activities, outcomes, and costs in Victoria, Australia. However, these changes were not statistically significant.
Background This review aimed to compare the relative effectiveness of different exercise-based cardiac rehabilitation (ExCR) delivery modes (centre-based, home-based, hybrid and technology-enabled ExCR) on key heartfailure (HF) outcomes: exercise capacity, health-related quality of life (HRQoL), HF-related hospitalisation and HF-related mortality.
Clinical presentation, shock severity and mortality in patients with de novo versus acute-on-chronic heartfailure-related cardiogenic shock. ACHF-CS, acute-on-chronic failure-related cardiogenic shock; CI, confidence interval; DNHF-CS, de novo heartfailure-related cardiogenic shock; HR, hazard ratio.
Background:The prevalence of risk factors for heartfailure and outcomes varies across racial and ethnic groups. Despite this variation, treatment guidelines for heartfailure are standardized, potentially overlooking the unique needs and responses of minority populations.
years]) admitted to the China Chest Pain Center Database between 2016 and 2021. The primary outcome was a composite of inhospital adverse events. Associations between multimorbidity patterns and outcomes were evaluated using multivariableadjusted logistic regression models.
Objective To evaluate stress, depression and quality of life among community-dwelling patients with heartfailure (HF) and evaluate their effect on perceived medication adherence in a socioeconomically challenged setting.
Methods A total of 469 consecutive patients undergoing TAVI between 2015 and 2021 were enrolled. The primary clinical outcome measure was all-cause mortality and heartfailure hospitalisation 1 year after TAVI. versus 2.0%, respectively (p<0.01), and that of heartfailure hospitalisation was 10.7%
Despite guideline recommendations for complete device removal, disparities in healthcare access and resource availability between urban and rural settings may influence patient outcomes. This study aims to evaluate ruralurban disparities in the management and outcomes of patients hospitalized with CIED infections. in rural hospitals.
Background:The STRACK project aims to improve post-stroke patient management and the transition from acute to primary care thanks to improvements in patient pathways and monitoring cardiovascular risk factors: heartfailure, diabetes, atrial fibrillation, dyslipidemia and hypertension.
Angiogram in 2021 was normal. Most patients with heartfailure with reduced ejection fraction and left bundle branch block with a QRS over 130 ms should get one. The patient awoke and had a good outcome! Old records still had not appeared. Could not obtain a previous 12-lead ECG even by calling the U. Initial trop ~200.
The Award will refer to articles published in 2021 and 2022. The Award will be given to the Brazilian authors of the best Original Article published in the ABC Cardiol and IJCS journals for the years 2021 and 2022, and to Brazilian authors of the best Original Article published in the ABC Imagem and ABC HF journals in 2022.
There will be an award for the most cited national manuscript in the last two years, namely: the most cited article published in 2021 and 2022 in 2023, for the journals ABC Cardiol and IJCS; and the most accessed in 2023 for the journals ABC Imagem and ABC HF. for enrollment in courses at the Heart University.
OSA disproportionately affects the 92 million Americans living with cardiovascular disease (CVD), often goes undiagnosed (1) , and doubles the risk for heartfailure and other serious cardiovascular conditions. American Heart Association (2021). Sleep apnea worsens heart disease, yet often untreated. billion (2).
Abstract Aims This study aimed to give contemporary insight into the use of Impella and venoarterial extracorporeal membrane oxygenation (VA-ECMO) in acute myocardial infarction-related cardiogenic shock (AMICS) and into associated outcomes, adverse events, and resource demands. Overall, adverse event rates and resource consumption were high.
Ten presentations will feature new data from the pivotal Phase III FINEARTS-HF cardiovascular (CV) outcomes trial, which investigated KERENDIA for treatingt adult patients with heartfailure (HF) with a left ventricular ejection fraction (LVEF) of 40%, i.e., mildly reduced LVEF (HFmrEF) or preserved LVEF (HFpEF).
Introduction Data on the characteristics and outcomes of pregnancy and among patients with Fontan physiology are limited. We aimed to evaluate the immediate and long-term outcomes among these patients who were followed at our centre. We examined maternal and obstetric outcomes. We examined maternal and obstetric outcomes.
The study, which is testing a novel rehabilitation program designed for older patients hospitalized with acute heartfailure, is funded by a five-year, $30 million grant , awarded to Wake Forest University School of Medicine in 2022 by the National Institute of Aging, part of the National Institutes of Health.
AI-enabled remote cardiac monitoring is is already revolutionizing how we detect, diagnose, mitigate and manage heart conditions. By enabling the decisive shift from a reactive to a proactive cardiology model, this technology doesnt just improve patient outcomes it is also helping keep cardiovascular care sustainable and affordable.
Ten presentations will feature new data from the pivotal Phase III FINEARTS-HF cardiovascular (CV) outcomes trial, which investigated KERENDIA for treatingt adult patients with heartfailure (HF) with a left ventricular ejection fraction (LVEF) of 40%, i.e., mildly reduced LVEF (HFmrEF) or preserved LVEF (HFpEF).
Background Currently, there is no head-to-head comparison of novel pharmacological treatments for heartfailure with reduced ejection fraction (HFrEF). Methods Randomised controlled trials (RCTs) were identified from Medline, Scopus up to June 2021.
Sodium-glucose cotransporter 2 inhibitors have demonstrated positive effects in heartfailure (HF) patients. Data regarding dapagliflozin administration from 70 patients diagnosed with HF between December 2020 and November 2021 at a Japanese heart centre were analysed retrospectively.
Journal of the American Heart Association, Ahead of Print. BackgroundTelemedicine interventions (TMIs) for heartfailure (HF) can reduce hospitalizations and deaths. It is unclear if low literacy and limited access to technology in low and middleincome countries affect these benefits.
One of these diseases is heartfailure – a condition in which the heart is unable to pump enough blood to the organs in our body. Unfortunately, the number of patients with heartfailure continues to grow. Of course, there is drug treatment for heartfailure, but it is not always sufficient.
Sodium-glucose cotransporter-2 inhibitors (SGLT2i) have been shown to reduce cardiovascular rehospitalisation in heartfailure with reduced ejection fraction (HFrEF) patients. A retrospective study of four hospitals in England involving 184 patients with HFrEF exacerbations between March 2021 and June 2022 was performed.
ABSTRACT Aims The aim of this analysis was to provide data on the overall comorbidity burden, both cardiovascular (CV) and non-CV, in a large real-world heartfailure (HF) population across the ejection fraction (EF). Methods and Results Patients with HF from the Swedish HF Registry between 2000-2021 were included.
A Brief Look at the Numbers Cardiovascular disease, a term that refers to all types of diseases that affect the heart or blood vessels, is responsible for over 800,000 deaths in the U.S. In 2021 alone, CVD accounted for over 900,000 deaths in the U.S. In 2021, approximately 57.8 and approximately 19.91 million globally.
AF-CHF trial in those with AF and congestive heartfailure also failed to show any advantage for the rhythm control strategy [3]. Overall, it appears that rhythm control strategy in AF may be better in those with heartfailure and in those with associated cardiovascular conditions and early AF.
BACKGROUND:Oral anticoagulation is suggested in patients with atrial fibrillation and a CHA2DS2-VASc score ≥1 (congestive heartfailure, hypertension, age ≥75 years, diabetes, stroke, vascular disease, age 65–74 years, and sex score). Circulation, Ahead of Print. Female sex was not considered a risk factor in any risk group.
A study published in JACC has compared the phenotypic expression and clinical outcomes in patients with arrhythmogenic cardiomyopathy [2]. Heartfailure, heart transplantation and death by cardiac causes were more often seen in individuals with biventricular phenotype compared to isolated left or right ventricular phenotype.
Combined with standard care and prevention of sudden cardiac death, these novel and emerging targeted therapies offer a possibility of improving the outcomes in several cardiomyopathies. It was based on an expert consensus reached at the HeartFailure Association online Workshop, held on 18 March 2021.
Aims Disease-related changes in body composition are associated with worse outcomes in chronic heartfailure. Methods and results We identified 160 consecutive patients with CA (transthyretin [ATTR] or light chain [AL]) diagnosed between 2001 and 2021 who had chest computed tomography within 1year before diagnosis.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
45 
Let's personalize your content